The purpose of this study is to evaluate the efficacy and safety of Tegileridine Fumarate lnjection for prolonged abirritation(48h to 72h) during mechanical ventilation in the ICU.
Patients or their guardians are able to provide a written informed consent
Subjects have been treated with endotracheal intubation and mechanical ventilation ≤24h, and then prolonged mechanical ventilation ≥48h in the next
Age ≥ 18 and ≤ 85 years, Male or female
Body mass index (BMI) > 18 and < 30 kg/m2
Those who are known or suspected to be allergic or contraindicated to various components of the experimental drugs involved in the research institute
With an expected survival time of less than 48 hours
unable to undergo CPOT and RASS assessments due to various reasons, such as a history of psychiatric disorders, neurological disorders, neurological dysfunction, and consciousness disorders, as well as blindness, deafness, or aphasia
Myasthenia gravis, bronchial asthma attack, acute intestinal obstruction, abdominal compartment syndrome